By using this website, you agree to the storing of cookies on your device. These cookies are used to collect information about how you interact with our website and allow us to remember you. We use this information in order to improve and customize your browsing experience and for analytics and metrics about our visitors both on this website and other media. To find out more about the cookies we use, see our Cookie Policy.
Slingshot’s revolutionary technology is a new paradigm for any cell-based application, including drug discovery, clinical trials, medical testing, and cell therapy manufacturing.
Drug development, diagnostics and adoptive cell therapies without limitations—that’s the world we envisioned when we founded this company over 10 years ago. We cut our teeth in academia, in R&D and in the clinics where we learned first-hand the limitations of biologically-derived cellular reagents: resource-intensive products that fall short in performance and accuracy, unstable and inconsistent over time, and a complex, ethically-challenged supply chain—all leading to unequal access to the most basic diagnostic testing and life-saving therapies.
We knew there had to be a better way. And there is.
We applied the tenets of biochemistry, high-precision manufacturing and polymer chemistry to create FlowCytes™. These shelf-stable, synthetic cells can be custom printed on demand, at scale, in real-time. Slingshot’s revolutionary technology decreases cost, shortens development timelines and increases stability, impact and accessibility. There is a new paradigm for drug development, diagnostics and cell therapy—one without limitations.
Advancing cell biology to develop innovative solutions for human health
Our vision is to advance the understanding of cell biology, especially in cancer and rare diseases, to help scientists and physicians focus on what they do best—creating innovative cures to treat patients.
Making medical testing simple and accessible
We aim to replace biological cells in medical and therapeutic industries that have been held back by limitations in sourcing, supply chain and bio-based reagents. In doing so, our vision is to simplify workflows in medical testing, remove cost barriers, and enable greater access to all patients-especially in underserved and developing countries.
Making personalized therapeutics a reality
We imagine a future where patients are treated with a drug that is personally designed for their needs. In that vision, our platform technologies will unlock the potential to custom design therapeutics quickly, reliably and at scale for our biopharma partners.
We’re building a passionate and dedicated team to make diagnostics and therapeutics more accessible.
